Thromb Haemost 2018; 118(02): 340-350
DOI: 10.1160/TH17-09-0676
Coagulation and Fibrinolysis
Schattauer GmbH Stuttgart

Chemical Footprinting Reveals Conformational Changes Following Activation of Factor XI

Ingrid Stroo
,
J. Arnoud Marquart
,
Kamran Bakhtiari
,
Tom Plug
,
Alexander B. Meijer
,
Joost C. M. Meijers
Further Information

Publication History

29 September 2017

29 November 2017

Publication Date:
29 January 2018 (online)

Abstract

Coagulation factor XI is activated by thrombin or factor XIIa resulting in a conformational change that converts the catalytic domain into its active form and exposing exosites for factor IX on the apple domains. Although crystal structures of the zymogen factor XI and the catalytic domain of the protease are available, the structure of the apple domains and hence the interactions with the catalytic domain in factor XIa are unknown. We now used chemical footprinting to identify lysine residue containing regions that undergo a conformational change following activation of factor XI. To this end, we employed tandem mass tag in conjunction with mass spectrometry. Fifty-two unique peptides were identified, covering 37 of the 41 lysine residues present in factor XI. Two identified lysine residues that showed altered flexibility upon activation were mutated to study their contribution in factor XI stability or enzymatic activity. Lys357, part of the connecting loop between A4 and the catalytic domain, was more reactive in factor XIa but mutation of this lysine residue did not impact on factor XIa activity. Lys516 and its possible interactor Glu380 are located in the catalytic domain and are covered by the activation loop of factor XIa. Mutating Glu380 enhanced Arg369 cleavage and thrombin generation in plasma. In conclusion, we have identified novel regions that undergo a conformational change following activation. This information improves knowledge about factor XI and will contribute to development of novel inhibitors or activators for this coagulation protein.

Note

This research was supported by grant PPOP-14–01 (Netherlands Ministry of Health).


 
  • References

  • 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30 (43) 10363-10370
  • 2 Kravtsov DV, Matafonov A, Tucker EI. , et al. Factor XI contributes to thrombin generation in the absence of factor XII. Blood 2009; 114 (02) 452-458
  • 3 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266 (12) 7353-7358
  • 4 von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86 (08) 3035-3042
  • 5 von dem Borne PA, Mosnier LO, Tans G, Meijers JC, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78 (02) 834-839
  • 6 Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 1977; 252 (18) 6432-6437
  • 7 Gailani D, Broze Jr GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253 (5022): 909-912
  • 8 McMullen BA, Fujikawa K, Davie EW. Location of the disulfide bonds in human coagulation factor XI: the presence of tandem apple domains. Biochemistry 1991; 30 (08) 2056-2060
  • 9 Geng Y, Verhamme IM, Messer A. , et al. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem 2012; 287 (45) 38200-38209
  • 10 Marcinkiewicz MM, Sinha D, Walsh PN. Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa. J Biol Chem 2012; 287 (09) 6187-6195
  • 11 Fujikawa K, Chung DW, Hendrickson LE, Davie EW. Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25 (09) 2417-2424
  • 12 Papagrigoriou E, McEwan PA, Walsh PN, Emsley J. Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 2006; 13 (06) 557-558
  • 13 Jin L, Pandey P, Babine RE. , et al. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions. J Biol Chem 2005; 280 (06) 4704-4712
  • 14 Jin L, Pandey P, Babine RE, Weaver DT, Abdel-Meguid SS, Strickler JE. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors. Acta Crystallogr D Biol Crystallogr 2005; 61 (Pt 10): 1418-1425
  • 15 Navaneetham D, Jin L, Pandey P. , et al. Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem 2005; 280 (43) 36165-36175
  • 16 Samuel D, Cheng H, Riley PW. , et al. Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation. Proc Natl Acad Sci U S A 2007; 104 (40) 15693-15698
  • 17 Sinha D, Seaman FS, Koshy A, Knight LC, Walsh PN. Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI. J Clin Invest 1984; 73 (06) 1550-1556
  • 18 Maas C, Meijers JC, Marquart JA. , et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A 2010; 107 (20) 9083-9087
  • 19 Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 1987; 262 (24) 11651-11656
  • 20 Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood 1992; 79 (06) 1435-1440
  • 21 Bloem E, Meems H, van den Biggelaar M, van der Zwaan C, Mertens K, Meijer AB. Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII. J Biol Chem 2012; 287 (08) 5775-5783
  • 22 Bloem E, van den Biggelaar M, Wroblewska A. , et al. Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake. J Biol Chem 2013; 288 (41) 29670-29679
  • 23 Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9 (07) 671-675
  • 24 Hemker HC, Giesen P, Al Dieri R. , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
  • 25 Pathak M, Wilmann P, Awford J. , et al. Coagulation factor XII protease domain crystal structure. J Thromb Haemost 2015; 13 (04) 580-591
  • 26 Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118 (26) 6963-6970
  • 27 Renné T, Gailani D, Meijers JC, Müller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem 2002; 277 (07) 4892-4899
  • 28 Baglia FA, Walsh PN. A binding site for thrombin in the apple 1 domain of factor XI. J Biol Chem 1996; 271 (07) 3652-3658
  • 29 Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 2010; 115 (13) 2569-2577
  • 30 Baglia FA, Jameson BA, Walsh PN. Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI. J Biol Chem 1993; 268 (06) 3838-3844
  • 31 Geng Y, Verhamme IM, Sun MF, Bajaj SP, Emsley J, Gailani D. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa. J Thromb Haemost 2013; 11 (07) 1374-1384
  • 32 Sun MF, Zhao M, Gailani D. Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. J Biol Chem 1999; 274 (51) 36373-36378
  • 33 Baglia FA, Jameson BA, Walsh PN. Identification and chemical synthesis of a substrate-binding site for factor IX on coagulation factor XIa. J Biol Chem 1991; 266 (35) 24190-24197
  • 34 Su YC, Miller TN, Navaneetham D, Schoonmaker RT, Sinha D, Walsh PN. The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2. J Biol Chem 2011; 286 (36) 31904-31914
  • 35 Cheng Q, Tucker EI, Pine MS. , et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116 (19) 3981-3989
  • 36 Wong SS, Østergaard S, Hall G. , et al. A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain. Blood 2016; 127 (23) 2915-2923
  • 37 Rezaie AR, Sun MF, Gailani D. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity. Biochemistry 2006; 45 (31) 9427-9433